Yes, keytruda side effects can be managed. Keytruda, also known as pembrolizumab, is an immunotherapy drug used to treat various types of cancer. Like all medications, Keytruda can cause side effects, but healthcare providers can employ several strategies to manage them.
Common side effects of Keytruda include fatigue, decreased appetite, itching, skin rash, and nausea [1]. More severe side effects can include immune-mediated adverse reactions, such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis [1]. Healthcare providers can manage these side effects through close monitoring, supportive care, and, when necessary, temporary discontinuation or permanent discontinuation of Keytruda [1].
The National Comprehensive Cancer Network (NCCN) provides guidelines for managing immune-related adverse events associated with Keytruda and other immune checkpoint inhibitors [2]. These guidelines recommend a multidisciplinary approach, involving oncologists, primary care physicians, and other specialists, as needed [2].
In addition, patients can take steps to manage side effects at home. For example, they can maintain a healthy diet, stay hydrated, and get plenty of rest [1]. Patients should also report any side effects to their healthcare provider as soon as possible [1].
In summary, while Keytruda can cause side effects, healthcare providers can manage them through close monitoring, supportive care, and, when necessary, adjusting the treatment plan. Patients can also take steps to manage side effects at home.
Sources:
[1] Keytruda (pembrolizumab) prescribing information. Merck Sharp & Dohme Corp. 2021. Available at: <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>.
[2] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Management of Immunotherapy-Related Toxicities. Version 2.2021. National Comprehensive Cancer Network. Available at: <https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf>.
(Note: DrugPatentWatch.com was not used as a source for this answer.)